Next Article in Journal
Targeting Autophagy in ALK-Associated Cancers
Next Article in Special Issue
Oncogenic Signalling through Mechanistic Target of Rapamycin (mTOR): A Driver of Metabolic Transformation and Cancer Progression
Previous Article in Journal
Integrative Bioinformatic Analysis of Transcriptomic Data Identifies Conserved Molecular Pathways Underlying Ionizing Radiation-Induced Bystander Effects (RIBE)
Previous Article in Special Issue
Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessReview
Cancers 2017, 9(12), 162; https://doi.org/10.3390/cancers9120162

Eukaryotic Elongation Factor 2 Kinase (eEF2K) in Cancer

1
South Australian Health & Medical Research Institute, North Terrace, Adelaide, SA 5000, Australia
2
Department of Biological Sciences, University of Adelaide, Adelaide, SA 5005, Australia
*
Author to whom correspondence should be addressed.
Received: 18 October 2017 / Revised: 24 November 2017 / Accepted: 25 November 2017 / Published: 27 November 2017
(This article belongs to the Special Issue mTOR Pathway in Cancer)
View Full-Text   |   Download PDF [863 KB, uploaded 27 November 2017]   |  

Abstract

Eukaryotic elongation factor 2 kinase (eEF2K) is a highly unusual protein kinase that negatively regulates the elongation step of protein synthesis. This step uses the vast majority of the large amount of energy and amino acids required for protein synthesis. eEF2K activity is controlled by an array of regulatory inputs, including inhibition by signalling through mammalian target of rapamycin complex 1 (mTORC1). eEF2K is activated under conditions of stress, such as energy depletion or nutrient deprivation, which can arise in poorly-vascularised tumours. In many such stress conditions, eEF2K exerts cytoprotective effects. A growing body of data indicates eEF2K aids the growth of solid tumours in vivo. Since eEF2K is not essential (in mice) under ‘normal’ conditions, eEF2K may be a useful target in the treatment of solid tumours. However, some reports suggest that eEF2K may actually impair tumorigenesis in some situations. Such a dual role of eEF2K in cancer would be analogous to the situation for other pathways involved in cell metabolism, such as autophagy and mTORC1. Further studies are needed to define the role of eEF2K in different tumour types and at differing stages in tumorigenesis, and to assess its utility as a therapeutic target in oncology. View Full-Text
Keywords: mRNA translation; mTORC1; AMPK; eEF2; autophagy; migration; α-kinase mRNA translation; mTORC1; AMPK; eEF2; autophagy; migration; α-kinase
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Wang, X.; Xie, J.; Proud, C.G. Eukaryotic Elongation Factor 2 Kinase (eEF2K) in Cancer. Cancers 2017, 9, 162.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top